Equities research analysts predict that Sabra Health Care REIT Inc (NASDAQ:SBRA) will announce $151.83 million in sales for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Sabra Health Care REIT's earnings, with estimates ranging from $149.48 million to $153.50 million. Sabra Health Care REIT posted sales of $149.83 million during the same quarter last year, which suggests a positive year over year growth rate of 1.3%. The company is scheduled to announce its next earnings report on Wednesday, November 4th.
According to Zacks, analysts expect that Sabra Health Care REIT will report full-year sales of $604.32 million for the current fiscal year, with estimates ranging from $594.75 million to $609.10 million. For the next fiscal year, analysts forecast that the business will report sales of $611.88 million, with estimates ranging from $605.83 million to $618.10 million. Zacks Investment Research's sales averages are a mean average based on a survey of sell-side research analysts that follow Sabra Health Care REIT.
Sabra Health Care REIT (NASDAQ:SBRA) last posted its earnings results on Wednesday, August 5th. The real estate investment trust reported $0.14 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.40 by ($0.26). Sabra Health Care REIT had a net margin of 21.00% and a return on equity of 3.78%.
Several analysts have recently issued reports on SBRA shares. Citigroup upped their price objective on Sabra Health Care REIT from $10.00 to $14.00 and gave the company a "neutral" rating in a research report on Thursday, July 2nd. Scotiabank upgraded Sabra Health Care REIT from a "sector underperform" rating to a "sector perform" rating and upped their price objective for the company from $12.00 to $15.00 in a research report on Tuesday, June 23rd. JMP Securities started coverage on Sabra Health Care REIT in a research report on Monday, June 8th. They issued a "market perform" rating on the stock. Stifel Nicolaus reiterated a "hold" rating and set a $15.00 target price on shares of Sabra Health Care REIT in a research report on Tuesday, September 1st. Finally, Zacks Investment Research upgraded Sabra Health Care REIT from a "hold" rating to a "buy" rating and set a $16.00 target price on the stock in a research report on Tuesday, August 25th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and five have assigned a buy rating to the company. The company has an average rating of "Hold" and a consensus price target of $17.40.
Several hedge funds have recently bought and sold shares of SBRA. Van ECK Associates Corp grew its stake in shares of Sabra Health Care REIT by 118.0% in the first quarter. Van ECK Associates Corp now owns 2,468 shares of the real estate investment trust's stock valued at $27,000 after buying an additional 1,336 shares in the last quarter. Whittier Trust Co. grew its stake in shares of Sabra Health Care REIT by 57.6% in the second quarter. Whittier Trust Co. now owns 2,736 shares of the real estate investment trust's stock valued at $39,000 after buying an additional 1,000 shares in the last quarter. Private Advisor Group LLC acquired a new stake in shares of Sabra Health Care REIT in the second quarter valued at about $60,000. Assetmark Inc. acquired a new stake in shares of Sabra Health Care REIT in the second quarter valued at about $72,000. Finally, Wedbush Securities Inc. acquired a new stake in shares of Sabra Health Care REIT in the second quarter valued at about $149,000. Institutional investors and hedge funds own 89.73% of the company's stock.
Shares of NASDAQ:SBRA opened at $15.08 on Monday. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 0.73. Sabra Health Care REIT has a 52-week low of $5.55 and a 52-week high of $24.95. The stock's fifty day simple moving average is $15.12 and its 200-day simple moving average is $13.78. The company has a market capitalization of $3.10 billion, a P/E ratio of 23.94 and a beta of 1.29.
The company also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Monday, August 17th were issued a $0.30 dividend. The ex-dividend date of this dividend was Friday, August 14th. This represents a $1.20 dividend on an annualized basis and a dividend yield of 7.96%. Sabra Health Care REIT's dividend payout ratio (DPR) is 64.52%.
Sabra Health Care REIT Company Profile
As of December 31, 2018, Sabra's investment portfolio included 470 real estate properties held for investment (consisting of (i) 335 Skilled Nursing/Transitional Care facilities, (ii) 90 Senior Housing communities (Senior Housing - Leased), (iii) 23 Senior Housing communities operated by third-party property managers pursuant to property management agreements (Senior Housing - Managed) and (iv) 22 Specialty Hospitals and Other facilities), one investment in a direct financing lease, 22 investments in loans receivable (consisting of (i) one mortgage loan, (ii) two construction loans, (iii) one mezzanine loan and (iv) 18 other loans), nine preferred equity investments and one investment in an unconsolidated joint venture that owns 172 Senior Housing - Managed communities.
Further Reading: What does RSI mean?
Get a free copy of the Zacks research report on Sabra Health Care REIT (SBRA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
15 Healthcare Stocks that Analysts Love
There are more than 200 healthcare companies traded on public markets. Given the sheer number of pharmaceutical companies, medical research firms, hospital systems and other healthcare stocks, it can be hard to identify which healthcare companies are going to outperform the market.
Fortunately, Wall Street's brightest minds have already done this for us. Every year, analyst issue approximately 3,000 distinct recommendations for healthcare companies. Analysts don't always get their "buy" ratings right, but it's worth taking a hard look when several analysts from different brokerages and research firm are giving "strong buy" and "buy" ratings to the same healthcare stock.
This slide show lists the 15 healthcare companies that have the highest average analyst recommendations from Wall Street's equities research analysts over the last 12 months.
View the "15 Healthcare Stocks that Analysts Love".